 INmune Bio, Inc. INMB, a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced today that the United States Patent and Trademark Office USPTO has given formal notice of allowance in patent application serial no. 15268,399, titled IN VIVO PRIMING OF NATURAL KILLER CELLS, which covers a method of treating cancer by administering a proprietary inactivated cellular material preparation and contacting a patients own natural killer cells within the body to induce an in vivo response, namely, the priming of NK cells for enhancing innate immunity and the NK cell ability to recognize and kill cancer cells within the patient. The newly allowed patent is expected to issue within ninety days and will be set to expire in 2036, subject to patent term adjustment or extension. 